Blog
DSIP: a small insomnia study with a cautious conclusion
The compound’s name is not proof of its effect. The strength and consistency of the overall result matter more than one positive measurement.
Evidence discussed: Small controlled human trial.
What the researchers studied
A double-blind study evaluated DSIP in 16 people with chronic insomnia. Researchers assessed sleep recordings, perceived sleep quality and tiredness. Some objective measurements favored DSIP, including sleep efficiency and time to fall asleep. [1]
How to interpret the result
The investigators considered the significant effects weak and potentially influenced by an incidental placebo-group change. Subjective sleep quality and several other measures did not improve. They concluded that short-term treatment was unlikely to offer major therapeutic benefit.
What readers can take from it
The compound’s name is not proof of its effect. The strength and consistency of the overall result matter more than one positive measurement.
This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.
Source
[1] Bes et al., DSIP in chronic insomnia (1992). PMID: 1299794. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.